---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-108909"
form_type: "8-K"
ticker: "HURA"
cik: "0001498382"
company_name: "TuHURA Biosciences, Inc./NV"
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T13:06:21.902135+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# TuHURA Q2 R&D $4.9M, initiates Phase 3 IFx-2.0 trial, acquires Kineta VISTA mAb

## Summary
- Completed acquisition of Kineta; VISTA mAb (TBS-2025) Phase 2 AML trial planned for 2H 2025.
- Initiated Phase 3 accelerated approval trial of IFx-2.0 with Keytruda in MCC under FDA SPA.
- Raised $12.5M equity financing plus $3.0M from warrant exercise in June 2025; shares outstanding ~49.9M.
- R&D expenses $4.9M (Q2 2025) vs $2.8M (Q2 2024); operating cash outflow ($10.9M) for 6 months.
- Added to Russell 3000/2000 indices in June 2025; targets Phase 3 topline results 2H 2026.

## SEC filing metadata
- accession: 0000950170-25-108909
- form_type: 8-K
- ticker: HURA
- cik: 0001498382
- company_name: TuHURA Biosciences, Inc./NV
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1498382/000095017025108909/0000950170-25-108909-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1498382/000095017025108909/hura-20250814.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-108909
- JSON: https://secwatch.observer/filing/0000950170-25-108909.json
- Plain text: https://secwatch.observer/filing/0000950170-25-108909.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.